{"disease":{"id":"lupus-nephritis-ln","name":"lupus nephritis ln"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06927219","title":"Research Accelerated by You Lupus Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Lupus Foundation of America","has_results":false},{"nct_id":"NCT06682507","title":"High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07363460","title":"Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06210464","title":"Disease and Biomarker Profiling of Chinese Lupus Nephritis","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Nan Shen","has_results":false},{"nct_id":"NCT05097989","title":"Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":100,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06588192","title":"Renal Survival in Patients with Lupus Nephritis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":97,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06975787","title":"Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06943937","title":"A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07491900","title":"A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hinge Bio","has_results":false},{"nct_id":"NCT06839976","title":"CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT07123519","title":"A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07104721","title":"A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT06585514","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07236762","title":"An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"China Immunotech (Beijing) Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07535138","title":"Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Air Force Military Medical University, China","has_results":false},{"nct_id":"NCT07000292","title":"MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT06902844","title":"Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05609812","title":"Atacicept in Subjects With Active Lupus Nephritis (COMPASS)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Vera Therapeutics, Inc.","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}